Dose-Dense Docetaxel Treatment Protocol in Prostate Cancer

In prostate cancer, docetaxel chemotherapy is an important treatment option, particularly in advanced disease, including metastatic or castration-resistant prostate cancer.

What Is Docetaxel? How Does It Work?

Docetaxel is a semisynthetic chemotherapy drug derived from the needles of the yew tree.

The drug binds strongly to microtubules, an important component of the cell's structural framework, and stabilizes them. This binding prevents the flexibility that microtubules normally need and stops cell division.

Docetaxel acts during mitosis, the division phase of the cell cycle. By stopping cells from dividing and multiplying, it inhibits cancer cell growth.

Docetaxel Indications in Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer

Indicated in patients whose disease progresses despite androgen deprivation therapy (ADT).

Conditions for Use:

• Rising PSA or increasing metastases despite hormonal therapy
• Patients with ECOG performance status 0–2
• Organ function adequate for treatment (bone marrow, liver, kidneys)

Key Study Supporting the Indication:

• TAX327 (Tannock et al., NEJM, 2004)
• Survival in the docetaxel + prednisone group: 18.9 months
• In the mitoxantrone + prednisolone group: 16.5 months
• PSA response rate was higher (45% vs 32%)
• Docetaxel + prednisolone received FDA approval based on these results.

Metastatic Hormone-Sensitive Prostate Cancer

Indicated in newly diagnosed patients with metastatic disease who have not yet started hormonal therapy.

Conditions for Use:

• High tumor burden (e.g., visceral metastases or more than 4 bone metastases)
• Performance status suitable for treatment (ECOG 0–1)
• Given with androgen deprivation (ADT + docetaxel)

Key Studies Supporting the Indication:

CHAARTED (Sweeney et al., NEJM, 2015):

• Median survival in the ADT + docetaxel group: 57.6 months
• In the ADT-only group: 44.0 months
• Marked benefit, particularly in patients with high tumor burden

STAMPEDE (Lancet, 2016):

• Compared ADT + docetaxel + zoledronic acid with ADT alone
• Longer survival and progression-free survival in the docetaxel group.

Purpose of Dose-Dense Docetaxel

Administering docetaxel every 2 weeks is an alternative dosing strategy to the standard 3-week regimen. This approach was developed to improve tolerability and potentially increase effectiveness in selected patient groups.

• Reducing Toxicity: The 2-week regimen uses a lower dose (usually 50 mg/m²), which may reduce side effects, particularly neutropenia, febrile neutropenia and neuropathy.
• Providing More Sustained Activity: More frequent chemotherapy administration aims to maintain more consistent tumor suppression.
• Better Tolerability in Older and Frail Patients: May be preferred in patients aged 75 and older, those with comorbidities or those with poor performance status, such as ECOG 2.
• Reduced Need for Supportive Treatment (in Some Studies): Some data have shown less need for G-CSF (against neutropenia), although it is generally still recommended.
• PROSTY study (2013): In metastatic castration-resistant prostate cancer, docetaxel every 2 weeks (50 mg/m²) was associated with less neutropenia and similar effectiveness.
• Byeon et al., BMC Cancer (2021): In newly diagnosed metastatic hormone-sensitive disease, docetaxel 40 mg/m² every 2 weeks combined with ADT was well tolerated, with a 95% PSA response rate.
• Martinez-Recio et al., 2022 (Clin Genitourin Cancer): Better tolerability and similar clinical outcomes were reported with the 2-week regimen in geriatric patients.

Dose Range

Standard Regimen:

• Dose: 75 mg/m²
• Frequency: Every 3 weeks
• Concomitant medication: Usually oral prednisolone (5 mg, 2 times a day)

Dose-Dense Regimen:

• Dose range: 40–50 mg/m²
• Administration frequency: Every 2 weeks

Dose selection is based on the patient's age, performance status (ECOG), comorbidities and response to previous treatment.

Special Situations Requiring Attention

• Risk of hematological toxicity (neutropenia, febrile neutropenia):  G-CSF prophylaxis should be considered.
• Dose adjustment in older and frail patients: If needed, treatment should start at 40 mg/m².
• Liver dysfunction: Docetaxel is metabolized in the liver; in severe impairment it should not be used, or the dose should be reduced.
• Patients with poor performance status (ECOG ≥2): Careful assessment is required before starting treatment.
• Risk of neuropathy:  Pre-existing peripheral neuropathy may require dose reduction or a change of treatment.
• Risk of allergic reactions: Premedication (e.g., dexamethasone) should be given before treatment.
• Attention to fluid balance during infusion: Fluid loading should be managed carefully, particularly in patients with heart failure.
• Treatment-related fatigue and loss of appetite: Nutritional and general supportive care should be planned.
• Nail changes and skin reactions: Skin care and supportive measures should be recommended.
• Regular assessment of treatment response: Assessment should use PSA, imaging (CT, bone scintigraphy) and clinical findings.
• Interactions with concomitant medications: Caution is needed particularly with drugs metabolized through CYP3A4.

Side Effects

• Neutropenia: 32–75%
• Febrile neutropenia: 3–20%
• Leukopenia: 30–40%
• Anemia: 10–30%
• Thrombocytopenia: 5–15%
• Fatigue: 40–70%
• Nausea: 20–50%
• Vomiting: 10–30%
• Diarrhea: 15–35%
• Mucositis (mouth sores): 10–25%
• Peripheral neuropathy: 10–30%
• Hair loss (alopecia): 50–90%
• Nail changes: 15–30%
• Allergic reactions: 1–5%
• Edema (swelling due to fluid retention): 10–25%
• Skin rash: 5–15%
• Taste changes: 5–10%
• Elevated liver enzymes: 5–20%
• Infection: 10–25%